Cart
sales@molnova.com
Home - Products - Others - Other Targets - Pritumumab

Pritumumab

CAS No. 499212-74-7

Pritumumab( —— )

Catalog No. M37296 CAS No. 499212-74-7

Pritumumab (ACA 11) is a natural human IgG1 κ antibody that can be used to study glioblastoma and brain tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 505 Get Quote
5MG 749 Get Quote
10MG 1123 Get Quote
25MG 1835 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Pritumumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Pritumumab (ACA 11) is a natural human IgG1 κ antibody that can be used to study glioblastoma and brain tumors.
  • Description
    Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    499212-74-7
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Hosenkoside F

    Hosenkoside F is a natural product from Impatiens balsamina L.

  • Magrolimab

    Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

  • Ciamexon

    Ciamexon (Ciamexone) is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.

Sign In Join Free